Advertisement

Neuroendocrine Carcinomas and Precursors

  • Elisabeth Brambilla
Part of the Molecular Pathology Library book series (MPLB, volume 1)

Abstract

Neuroendocrine lung tumors are usually classified into four histologic types that were shifted in the World Health Organization classification into three entities: small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), and carcinoids (typical and atypical).1,2 This subset of tumors shares morphologic, ultrastructural, immunohistochemical, and molecular characteristics. The four main types neuroendocrine lung tumors show varying degrees of neuroendocrine morphologic features, and they behave according to three grades of clinical aggressivity, the low-grade typical carcinoids, the intermediate-grade atypical carcinoids, and the high-grade LCNECs and SCLCs, which share many features including epidemiologic growth factor and oncogenic pathways. However, the concept of a continuous spectrum from carcinoid to SCLC has no other scientific basis than a common neuroendocrine differentiation.

Keywords

Vascular Endothelial Growth Factor Carcinoid Tumor Neuroendocrine Carcinoma Small Cell Lung Carcinoma Atypical Carcinoid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Travis WD, Colby TV, Corrin B, et al. WHO Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours, 3rd ed. Berlin: Springer-Verlag; 1999.Google Scholar
  2. 2.
    Travis WD, Brambilla E, Muller-Hemerlink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.Google Scholar
  3. 3.
    Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285–2290.CrossRefPubMedGoogle Scholar
  4. 4.
    Debelenko LV, Swalwell JI, Kelley MJ, et al. MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 2000;28:58–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529–553.PubMedCrossRefGoogle Scholar
  6. 6.
    Lantuejoul S, Moro D, Michalides RJ, et al. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 1998;22:1267–1276.CrossRefPubMedGoogle Scholar
  7. 7.
    Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934–944.CrossRefPubMedGoogle Scholar
  8. 8.
    Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999;12:5–8.PubMedGoogle Scholar
  9. 9.
    Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815–819.CrossRefPubMedGoogle Scholar
  10. 10.
    Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33:175–182.CrossRefPubMedGoogle Scholar
  11. 11.
    Wick MR. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 2000;17:194–203.PubMedGoogle Scholar
  12. 12.
    Pelosi G, Fraggetta F, Sonzogni A, et al. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virchows Arch 2000;437:270–274.CrossRefPubMedGoogle Scholar
  13. 13.
    Pelosi G, Leon ME, Veronesi G, et al. Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors. J Thorac Oncol 2006;1(5):468–477.CrossRefPubMedGoogle Scholar
  14. 14.
    Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 2000;31:980–987.CrossRefPubMedGoogle Scholar
  15. 15.
    Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001;32:918–925.CrossRefPubMedGoogle Scholar
  16. 16.
    Onuki N, Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999;85:600–607.CrossRefPubMedGoogle Scholar
  17. 17.
    Ullmann R, Schwendel A, Klemen H, et al. Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization. Hum Pathol 1998;29:1145–1149.CrossRefPubMedGoogle Scholar
  18. 18.
    Walch AK, Zitzelsberger HF, Aubele MM, et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol 1998;153:1089–1098.PubMedGoogle Scholar
  19. 19.
    Beasley MB, Lantuejoul S, Abbondanzo S, et al. The p16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34:136–142.CrossRefPubMedGoogle Scholar
  20. 20.
    Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941–1952.PubMedGoogle Scholar
  21. 21.
    Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996;148:1531–1541.PubMedGoogle Scholar
  22. 22.
    Eymin B, Claverie P, Salon C, et al. p14ARF activates a Tip60-dependent ATM/ATR/CHK pathway in response to genotoxic stresses. Mol Cell Biol 2006;26(11):4339–4350.CrossRefPubMedGoogle Scholar
  23. 23.
    Eymin B, Gazzeri S, Brambilla C, et al. Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002;21:2750–2761.CrossRefPubMedGoogle Scholar
  24. 24.
    Shivapurkar N, Toyooka S, Eby MT, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002;1:54–58.Google Scholar
  25. 25.
    Zaffaroni N, De Polo D, Villa R, et al. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol 2003;201:127–133.CrossRefPubMedGoogle Scholar
  26. 26.
    Zaffaroni N, Villa R, Pastorino U, et al. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres. Clin Cancer Res 2005;11(8):2832–2839.CrossRefPubMedGoogle Scholar
  27. 27.
    Sartelet H, Decaussin M, Devouassoux G, et al Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 (Flt-1) and VEGF-R2 (KDR/Flk-1) in tumorlets and in neuroendocrine cell hyperplasia of the lung. Hum Pathol 2005;35(10):1210–1217.CrossRefGoogle Scholar
  28. 28.
    Brambilla E, Constantin B, Drabkin H, et al. Semaphorin SEMA3F localization in malignant human lung and dividing cells: a suggested role in cell adhesion and cell migration. Am J Pathol 2000;156(3):939–950.PubMedGoogle Scholar
  29. 29.
    Kusy S, Nasarre P, Chan D, et al. Selective suppression of in vivo tumorigenicity by semaphoring SEMA3F in lung cancer cells. Neoplasia 2005;7(5):457–465.CrossRefPubMedGoogle Scholar
  30. 30.
    Salon C, Moro D, Lantuejoul S, et al. The E-cadherin/β-catenin adhesion complex in neuroendocrine tumors of the lung: a suggested role upon local invasion and metastasis. Hum Pathol 2004;35(9):1148–1155.CrossRefPubMedGoogle Scholar
  31. 31.
    Clavel CE, Nollet F, Berx G, et al. Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours. J Pathol 2001;194:20–26.CrossRefPubMedGoogle Scholar
  32. 32.
    Sanders DS, Perry I, Hardy R, et al. Aberrant E-cadherin expression in a feature of clonal expansion in the gastrointestinal tract associated with repair and neoplasia. J Pathol 2000;190:526–530.CrossRefPubMedGoogle Scholar
  33. 33.
    Institute of Pathology “Rudolf-Virchow-Haus.” Comparative Genomic Hybridization (CGH). 2003. University Hospital Charité Humboldt-University of Berlin. http://amba.charite.de/cgh/. Accessed February 12, 2007.Google Scholar
  34. 34.
    Ullmann R, Petzmann S, Sharma A, et al. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol 2001;32:1059–1063.CrossRefPubMedGoogle Scholar
  35. 35.
    Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993;143:199–210.PubMedGoogle Scholar
  36. 36.
    Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999;188:351–360.CrossRefPubMedGoogle Scholar
  37. 37.
    Eymin B, Karayan L, Seite P, et al. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001;20:1033–1041.CrossRefPubMedGoogle Scholar
  38. 38.
    Eymin B, Gazzeri S, Brambilla C, et al. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001;20:1678–1687.CrossRefPubMedGoogle Scholar
  39. 39.
    Viard-Leveugle I, Veyrenc S, French LE, et al. Frequent loss of Fas expression and function in human lung tumors with overexpression of FasL in small cell lung carcinoma. J Pathol 2003;(201)2:268–277.CrossRefPubMedGoogle Scholar
  40. 40.
    Rossi G, Cavazza A, Marchioni A, et al. Role of the chemotherapy and the receptor tyrosine kinases KIT, PDGFRα, PDGFRβ and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2 2005;23(34):8774–8785.CrossRefGoogle Scholar
  41. 41.
    Nawrocki B, Polette M, Van Hengel J, et al. Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol 1998;153:1521–1530.PubMedGoogle Scholar
  42. 42.
    Finkelstein SD, Hasegawa T, Colby T, et al. 11q13 allelic imbalance discriminates pulmonary carcinoids from tumor-lets. A microdissection-based genotyping approach useful in clinical practice. Am J Pathol 1999;155:633–640.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Elisabeth Brambilla
    • 1
  1. 1.Department of Pathology, CHU de Grenoble Albert Michallon, Lung Cancer Research GroupINSERM U578GrenobleFrance

Personalised recommendations